PAUL E SCHACKMAN

Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease UNION, NJ NPI 1144216342

General Payments — all program years on this page

$2,264.71

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 150
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $299.85 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $299.8518

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $746.3453
2019 $575.0644
2020 $164.6812
2021 $87.456
2022 $27.902
2023 $363.4315
2024 $299.8518

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1087270835 Novartis Pharmaceuticals Corporation $16.33 04/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087270857 Novartis Pharmaceuticals Corporation $17.77 10/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1092254581 Boston Scientific Corporation $28.58 10/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104524580 AstraZeneca Pharmaceuticals LP $13.87 06/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104530390 AstraZeneca Pharmaceuticals LP $14.42 07/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104668903 AstraZeneca Pharmaceuticals LP $15.00 02/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105248827 AstraZeneca Pharmaceuticals LP $16.95 11/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116093000 Amgen Inc. $15.32 02/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116093007 Amgen Inc. $13.43 04/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116093014 Amgen Inc. $17.78 08/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116093021 Amgen Inc. $15.08 09/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117888517 Boehringer Ingelheim Pharmaceuticals, Inc. $13.16 07/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117888519 Boehringer Ingelheim Pharmaceuticals, Inc. $15.23 02/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117888521 Boehringer Ingelheim Pharmaceuticals, Inc. $15.74 10/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141709953 Merck Sharp & Dohme LLC $20.24 11/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141710095 Merck Sharp & Dohme LLC $19.08 09/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154872281 Kiniksa Pharmaceuticals International, plc $14.88 03/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154872299 Kiniksa Pharmaceuticals International, plc $16.99 05/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.